LymPro Test: Pilot trial data

Preliminary data from 125 blood samples from 59 AD patients and 66 controls in the U.S. pilot LP-002 trial showed that the LymPro test met the primary endpoint of replicating data published in peer-reviewed publications. Specifically, the LymPro Test had 87% sensitivity and 83% specificity for distinguishing AD from healthy controls in a training set (n=81) and 76% sensitivity and 70% specificity in a test set (n=44). The study was comparing results to peer-reviewed results stating the best clinical result was 70.9% sensitivity and 70.8% specificity. Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, also said that the LymPro test met the secondary endpoints in the trial. Data were presented at the Alzheimer’s Association International Conference in Washington, D.C. ...